Fluicell Email Format
Biotechnology ResearchVästra Götaland, Sweden11-50 Employees
Fluicell develops tissue-based solutions for regenerative medicine and drug screening, anchored by the Nexocyte platform that produces precision-engineered tissues. The work is built on roughly twenty years of R&D with patent protection to advance transplantable tissues aimed at addressing tissue damage from diseases affecting the heart, lungs, metabolism, kidneys, and other organs, including an objective to develop tissues to treat type 1 diabetes. Nexocyte-generated tissues also support collaborators in advancing their drug-screening capabilities. Based in Mölndal, Västra Götaland, Sweden, Fluicell is a small to mid-sized biotechnology research company. In 2022, the company introduced a new high-precision bioprinting system to expand its tissue fabrication capabilities and support its work in regenerative medicine and drug discovery.